🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

ALS is progressing all the time. It is unrelenting. But so are we. We embody hope together so that we can strike out ALS. #ALSMNDWithoutBorders #embodyhopetogether #ALSawareness

I'm very proud of what we've been able to accomplish - bringing care to patients at this level from where we were when I started working in ALS. It's been probably the most rewarding aspect of my career.

📢Participants urgently needed for study of imaging biomarkers for Friedrich’s Ataxia. These are critical to assessing novel treatments in future clinical trials. Only 3 required visits in MTL. Participants from 🇨🇦 or 🇺🇸 welcome; travel costs covered. cru.mcgill.ca.

The CRU's Dr. Massimo Pandolfo spoke to CityNews about an international study on #FriedreichsAtaxia which aims to develop imaging #biomarkers to track disease progression more accurately and better assess potential treatments in future #clinicaltrials. montreal.citynews.ca/video/2023/08/…

Dr. Angela Genge spoke at Critical Path Institute (C-Path)'s #RareDisease Conference in DC this week, highlighting the need for novel #biomarker development to determine early evidence of target engagement in #ALS and the need for improved clinical outcome measures. #cpath

I am honoured to have been invited by European Brain Council to speak on this important topic. Individuals with MND need us to work together globally to speed up access to new treatments.

Dr. Pandolfo from The Neuro now speaking at #wcn2023 about Friedreich #ataxia, a rare neurological disorder. Only one treatment is approved and that one only by FDA. Others are in different stages of clinical trial.

Dr. Angela Genge from NeuroCRU now part of panel at #wcn2023 discussing how doctors and health professionals can best deliver news of an #ALS diagnosis.

#CTQ is a terrific initiative to help patients access #clinicaltrials more easily. And Catalis continues to propel the #lifesciences ecosystem in Quebec.

Fiers d'avoir participé à #RCQ : un nouveau pôle d'info en #rechercheclinique développé par le Réseau @CATALISquebec en partenariat avec le gouv du Qc. RCQ offre un Registre des #essaiscliniques, un accompagnement personnalisé pour patients, et plus.📲 bit.ly/49qb4yk

Our deepest gratitude to @Genge_angela who stepped down as CRU director after 19 years. Her dedication to patients transformed a small unit into a leading intl centre. Her unique vision and energy will always be part of our DNA. She remains director of The Neuro's ALS clinic.

I’ll be speaking at Globe and Mail Events’ AI in Medicine Tuesday at 12:30. This free event will cover opportunities and considerations related to the use of AI in medicine, and what it means for health care providers and patients. To sign up: tgam.ca/3t3b1YU#GlobeM…

AngelaGenge, director of ALS Centre of Excellence at The Neuro will be speaking Globe and Mail Events' AI in Medicine panel tomorrow at 12:30 on the promise of AI to transform speed and accuracy in detecting rare disorders. Free to register: tgam.ca/3t3b1YU #GlobeMedicine

Grateful for the opportunity to speak on personalized medicine and innovations in clinical trial design at the International Symposium on ALS/MND in Basel last week. #ALS #MND #PersonalizedMedicine #ClinicalTrials #Neurology #RareDisease

The #ALS Centre of Excellence The Neuro offers multidisciplinary care and early access to leading clinical trials. Thank you to all our supporters who help foster novel approaches to treatment + initiatives to support quality of life. ALS Canada Brain Canada SLA Québec

I’m thrilled to share that I have received a full professorship in the Department of Neurology and Neurosurgery at McGill University! McGill University McGill Medicine and Health Sciences #neurology #mcgill

All #rarediseases should be treatable. Working towards effective therapies is essential. Each year, NeuroCRU adds new conditions to its list of trials, like #MOGAD, #FSHD, #Huntingtons and #CJD. Patients deserve the option of accessing investigational treatments. #RareDiseaseDay

Grateful to have had the chance to discuss how new technologies, a better understanding of the underlying drivers of motor neuron cell death and the development of a #biomarker driven approach is leading to real progress in treatments of #ALS at #adpd2024 .

The Saguenay region of Quebec has the highest prevalence of #MyotonicDystrophy in the world (1 in 400). Several new #clinicaltrials on #DM1 at the CRU are testing #ASO-based therapies that, if successful, would offer the first disease modifying treatment. cru.mcgill.ca/nm

Dr. Simon Ducharme spoke to Andrew Carter CJAD yesterday about the 1st #genetherapy trial in Canada for #dementia. This landmark study for #FTD uses a viral vector to deliver a working copy of the #GRN gene to affected individuals. #theneuro omny.fm/shows/cjad-800…